TIDMAPOL
RNS Number : 8279Z
Apollon Formularies plc
27 January 2022
27 January 2022
Apollon Formularies Announces Appointment of Dr. Herbert
Fritsche, Former Professor of Laboratory Medicine and Chief of the
Clinical Chemistry Section at the University of Texas, MD Anderson
Cancer Center in Houston, Texas to the Board of Directors
-- Dr. Fritsche is the Chief Science Officer of Apollon
Formularies Jamaica Ltd (Non-Executive Director)
Apollon Formularies plc (AQSE: APOL, "Apollon" or the
"Company"), a UK based international medical cannabis
pharmaceutical company trading on AQSE Growth Market, is pleased to
announce the appointment of Dr. Herbert Fritsche to the Board of
Directors. Dr. Fritsche is a world-renowned Clinical Chemist and
former Professor of Laboratory Medicine and Chief of the Clinical
Chemistry Section at The University of Texas, MD Anderson Cancer
Center in Houston, Texas for 41 years.
Dr. Fritsche served as an invited consultant/advisor to the Food
and Drug Administration, the National Cancer Institute, the
Laboratory Practice Guidelines Committee for the National Academy
of Clinical Biochemistry, the Editorial Board of six international
scientific journals, and as a consultant to many major
international diagnostic companies. Previously, he served on the
Expert Panel for developing Tumor Marker Practice Guidelines for
the American Society of Clinical Oncology (ASCO) from its inception
until his retirement from MD Anderson Cancer Center.
His awards include the Johnson and Johnson Award for Outstanding
Research and Contributions to Clinical Biochemistry from the
National Academy of Clinical Biochemistry, the Abbott-ISOBM Award
for Outstanding Research in Oncology, the Morton K Schwartz Award
for Outstanding Achievements in the field of Cancer Diagnostics
from the American Association for Clinical Chemistry ("AACC"), the
Carl Jolliff Award for Lifetime Achievements in Immunology and
Immunodiagnostics from the Immunology Division of the AACC, the
Morton K Schwartz Award for significant contributions to the
development of cancer diagnostics from the New York Metro Division
of the AACC, the Outstanding Clinical Chemist Award by the Texas
Section of the AACC, the National Award for Contributions in
Education by the AACC, the Dean's Excellence Award from the
University of Texas Graduate School of Biomedical Science, and the
Distinguished Scientist Award from the Clinical Ligand Assay
Society ("CLAS").
Dr. Fritsche has served as President of the CLAS and various
national committees for both the CLAS and AACC. He is a Fellow of
the National Academy of Clinical Biochemistry.
He has published over 200 peer-reviewed scientific papers,
invited articles and book chapters, and participated in the
validation and FDA clearance process for almost every commercial
serum cancer marker currently in use in the United States. Dr.
Fritsche holds three patents and two patents pending.
Dr. Fritsche has lectured extensively for many years at
international and national meetings of medical and professional
societies, and he is recognized internationally as an expert in the
field of clinical chemistry, cancer diagnostics and laboratory
medicine.
"Dr. Fritsche is a highly respected international authority in
clinical chemistry and one of the world's leading experts on cancer
biomarkers, whom I have had the honor of working with for more than
30 years. We are extremely pleased that he has agreed to join our
Board of Directors," stated Stephen D. Barnhill, MD. Executive
Chairman and CEO of Apollon Formularies plc. "Dr. Fritsche and I
have been working together for the past eight years in
pharmaceutical medical cannabis including the development of the
formulations that were recently shown to be successful in
independent, 3(rd) party pre-clinical cancer testing at BIOENSIS
laboratories. We have also co-authored numerous peer-reviewed
publications. I'm excited to continue working with Dr. Fritsche on
the development of new pharmaceutical medical cannabis formulations
and testing the efficacy of these medicines in human clinical
trials."
"Dr. Barnhill is a scientific visionary having brought together
the fields of medicine and mathematics in a way that has, and will,
continue to benefit patients worldwide. Dr. Barnhill is the
earliest proponent of the use of artificial intelligence in
medicine and he is considered an international expert in this new
field of medicine. It has been a great pleasure to work with him on
cutting edge scientific discovery for more than 30 years," stated
Dr. Herbert Fritsche, "As a pioneer in artificial intelligence
techniques in medicine and an inventor on more than 40 patents in
this field, Dr. Barnhill now focuses his AI efforts on developing
medical cannabis pharmaceutical formulations. I look forward to
continuing our efforts to develop state-of-the-art technology and
unique medical cannabis pharmaceutical formulations to help
patients worldwide."
The Company would also like to advise that to facilitate Herbs
appointment Kevin Sheil will step aside at the same time to pursue
other business interests. The board of Apollon would like to thank
Kevin for his contribution since our IPO in April 2021 and we wish
him the best for his future endeavors.
Further information on Herbert Fritsche, Ph.D (Born: 30 November
1941)
Herbert has no current directorships and has not held any in the
past five years.
Except as set out above, there is no further information
regarding Herbert Fritsche, that is required to be disclosed
pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.
Herbert has no interest in the issued share capital of the
Company.
Further Information
On 19 July 2021, Apollon announced that its proprietary medical
cannabis formulations were shown in third party independent
clinical laboratory testing to be effective in killing both
hormone-resistant and hormone-sensitive prostate cancer cells in 3D
cell cultures by direct cytotoxicity.
June 28, 2021, Apollon announced that its proprietary medical
cannabis formulations were shown in third party independent
clinical laboratory testing to be effective in killing
triple-negative breast cancer cells in 3D cell culture by direct
cell cytotoxicity.
May 18, 2021, Apollon announced that its proprietary medical
cannabis formulations were shown in third party independent
clinical laboratory testing to be effective in killing HER2+ breast
cancer cells in 3D cell culture by direct cytotoxicity.
ENDS
The Directors of the Company accept responsibility for the
contents of this announcement.
For additional information, please visit www.apollon.org.uk or
contact:
Apollon Formularies
Tel: +44 7711 980 221
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe tim.blythe@blytheweigh.com
Megan Ray megan.ray@blytheweigh.com
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis
pharmaceutical company headquartered in the United Kingdom. Apollon
Formularies Jamaica, Ltd is a pharmaceutical company incorporated
and operating in the Commonwealth of Jamaica and a contractual
affiliate of Apollon. Apollon Jamaica is licensed by the Jamaican
government's Cannabis Licensing Authority (CLA) to purchase
cannabis under tripartite agreements from licensed cultivators,
process, perform research and development, and sell medical
cannabis therapeutic products that include legal medical cannabis
in order to treat various illnesses under medical supervision.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXBRMFTMTATMPT
(END) Dow Jones Newswires
January 27, 2022 02:00 ET (07:00 GMT)
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Feb 2023 to Mar 2023
Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2022 to Mar 2023
